If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Cyramza Summary of Product Characteristics (SmPC)
were randomly assigned (2:1) to receive ramucirumab 8 mg/kg IV
plus BSC (n=197) or placebo plus BSC (n=95) every 14 days until
disease progression or unacceptable toxicity, or until
discontinuation criteria were met.1
were excluded from participation in the REACH-2 study if they had a
prior liver transplant.2
Zhu AX, Kang YK, Yen CJ, et al. REACH-2: A randomized, double-blind,
placebo-controlled phase 3 study of ramucirumab versus placebo as
second-line treatment in patients with advanced hepatocellular
carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP)
following first-line sorafenib. Presented as an oral presentation at:
54th Annual Meeting of the American Society of Clinical Oncology
(ASCO); June 1-5, 2018; Chicago, IL. Abstract #4003.